SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

ronde-cel

LYEL·Lyell Immunopharma, Inc
BULLISH
Drug Impact Rating7/10
Trial phase
Phase 3
Time to market
Pivotal data from the PiNACLE trial is expected mid-2027, with a BLA submission planned for the second half of 2027. If approved, commercial launch would likely follow in 2028.
Why 7/10
The next hard, dated catalyst is the ASH 2026 Annual Meeting (December 12-15, 2026), where updated data from the PiNACLE pivotal trial and Phase 1/2 second-line cohort will be presented. Ronde-cel is Lyell's lead and essentially only late-stage asset, making this a high-concentration event. The proximity (~5 weeks) and the drug's centrality to the company's valuation justify a 7, though the catalyst is a conference data presentation rather than a regulatory binary decision.
Actionable Insight BULLISH

The next major catalyst is the ASH 2026 Annual Meeting (December 12-15, 2026), where updated data from the PiNACLE pivotal trial (3L+) and the Phase 1/2 second-line cohort will be presented in oral and poster sessions. Strong data could drive the stock toward analyst targets (mean $37.88), while disappointing durability or safety signals would pressure shares. The pivotal data readout expected in mid-2027 and BLA submission in H2 2027 are the longer-term binary events.

Price Chart

Loading chart...

Executive Summary

Ronde-cel (rondecabtagene autoleucel) is Lyell Immunopharma's next-generation, dual-targeting CD19/CD20 CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (LBCL). In the ongoing PiNACLE pivotal trial (3L+ setting), ronde-cel showed a 91% overall response rate and 77% complete response rate among 44 evaluable patients, with no Grade 3 or higher cytokine release syndrome (CRS) and low rates of severe neurotoxicity. The company raised $80 million in November 2026 to fund the program toward a planned BLA submission in the second half of 2027. Updated data from more than 80 patients will be presented at the ASH 2026 Annual Meeting (December 12-15, 2026).

How It Works

Ronde-cel is a personalized cell therapy (CAR T-cell) made from a patient's own immune cells. The cells are genetically engineered to carry two targeting molecules (CD19 and CD20) that recognize and attack cancerous B cells in lymphoma. It is designed to improve durability of response by enriching for stem-like T cells (CD62L+) and to reduce severe side effects compared to existing single-target CAR T therapies.

Trial Status

Two pivotal trials are underway: PiNACLE (single-arm, 3L+ LBCL) and PiNACLE-H2H (randomized Phase 3 head-to-head vs approved CD19 CAR T therapies in 2L LBCL). As of the Q3 2026 data cutoff, 44 patients were efficacy-evaluable in the 3L+ PiNACLE trial, showing 91% ORR and 77% CR. The 2L cohort showed a 95% ORR. Safety data across more than 100 patients showed no Grade >=3 CRS and low rates of severe ICANS, supporting potential outpatient administration. Manufacturing success rate is 97%.

The Two-Sided Case

▲ Bull Case5
Ronde-cel's 91% ORR and 77% CR in 3L+ LBCL compare favorably to approved CAR T therapies, with a differentiated safety profile (no Grade >=3 CRS) that could support outpatient administration and a competitive advantage.
The dual-targeting CD19/CD20 design and CD62L enrichment strategy may address the durability limitations of first-generation CAR T therapies, potentially offering longer-lasting responses.
Analyst consensus is strongly bullish: 12 of 14 analysts rate it Buy/Strong Buy, with a mean price target of $37.88 (152.5% upside from the $15 close on Nov 5, 2026).
The $80M private placement (at $10.77/share) from blue-chip healthcare investors (ARCH, Adage, RTW) extends cash runway into 2028, past the planned BLA submission, removing near-term financing risk.
Fast Track designation from FDA (May 2026) provides enhanced regulatory interaction and potential accelerated approval pathways.
▼ Bear Case5
Ronde-cel is still unapproved and faces a competitive market dominated by Yescarta (Gilead), Breyanzi (BMS), and Kymriah (Novartis), all established CD19 CAR T therapies with multi-billion-dollar sales and years of real-world data.
The PiNACLE trial is single-arm (not randomized) in the 3L+ setting, which may raise the bar for FDA approval if durability data at the pivotal readout (mid-2027) does not clearly exceed existing therapies.
The company is pre-revenue and posted a net loss of $45.5M in Q3 2026 alone. Despite the recent financing, additional dilution may be needed to fund commercialization.
Insider selling by the CEO, CSO, COO, and CMO in August-October 2026 (at prices from $8.63 to $15.54) signals some internal profit-taking ahead of key catalysts.
The stock has high volatility (52-week range $7.20-$45) and the recent 43% single-day surge on Nov 4 may reflect short-term positioning ahead of ASH rather than sustainable value.

Upcoming Catalysts

  • ASH 2026 Annual Meeting (December 12-15, 2026): Oral and poster presentations of updated ronde-cel data from PiNACLE pivotal trial (3L+) and Phase 1/2 2L cohort in more than 80 patients.
  • PiNACLE pivotal data readout (mid-2027): The primary efficacy analysis expected to support BLA submission.
  • BLA submission to FDA (H2 2027): Planned regulatory filing for ronde-cel in 3L+ R/R LBCL.
  • PiNACLE-H2H Phase 3 head-to-head trial: Ongoing randomized trial vs Yescarta/Breyanzi in 2L LBCL; future readout.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Lyell Immunopharma, Inc Press Release LYEL ·Originating report

Sources · 8

Hover a chip for the title
1 ir.lyell.com2 biospace.com3 trial.medpath.com4 lyell.com5 genomeweb.com6 sec.gov7 ash2026.myexpoonline.com8 lyell.com